Start-up
new/era/mabs GmbH
About new/era/mabs
new/era/mabs is offering new and innovative technologies for the generation of monoclonal and recombinant antibodies. Our selection technology is patented and allows an easy and efficient screening and sorting of desired antibody producing cells in a very short time frame. Together with our immunisation strategy of chimeric viral particles we are able to serve you with your specific antibody in a very fast manner. Our portfolio includes the generation of murine, camelid and human antibodies and different recombinant formats.
- Founding: 2014
- Focus : Manufacturer
- Employees: 1-10
- Industry : Biotechnology
Product portfolio of new/era/mabs
Here you will find new/era/mabs GmbH
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
